A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer

Simple item page
dc.contributor.authorOlver, I.
dc.contributor.authorDavy, M.
dc.contributor.authorLuftner, D.
dc.contributor.authorPark, S.
dc.contributor.authorEgorin, M.
dc.contributor.authorEllis, A.
dc.contributor.authorWebster, L.
dc.date.issued2001
dc.description.abstractPurpose: The efficacy and pharmacokinetics of paclitaxel when combined with altretamine for ovarian cancer were studied. Methods: A group of 30 patients, whose only chemotherapy was one or more cisplatin-based non-paclitaxel-containing regimens and whose ovarian cancer failed to respond or had relapsed within 6 months of their last platinum regimen, received paclitaxel as a 3-h intravenous infusion and altretamine given orally in four divided doses daily for 14 days repeated every 28 days. Doses were escalated from paclitaxel/altretamine 135/150 mg/m2 to 250/300 mg/m2 in cohorts of three patients. Results: The dose-limiting toxicities at 250/300 mg/m2 were WHO grade 3 myalgias and arthralgias in two patients and grade 3 lethargy, stomach cramps, peripheral neuropathy and vomiting in single patients. Considering all dose levels in cycle 1, 16 patients had grade 3 or 4 neutropenia but there was only one episode of febrile neutropenia. Other grade 3 toxicities were vomiting in four patients, myalgias in three, peripheral neuropathy in two and lethargy in two. Grade 3 alopecia occurred in 23 patients. Three patients achieved a complete response and 12 achieved a partial response for an overall objective response rate of 50%. Responses occurred at all dose levels of 175/150 mg/m2 and higher. The median freedom from progression was 35 weeks, with a median survival of 55 weeks. Altretamine did not alter the pharmacokinetics of paclitaxel and there were no consistent differences in paclitaxel pharmacokinetic parameters or toxicities between course 1 and 2. No dose-response relationships were evident above paclitaxel/altretamine 175/150 mg/m2. Conclusion: Paclitaxel and altretamine can be safely combined and with a high response rate in relapsed ovarian cancer, justifying further studies with this combination.
dc.description.statementofresponsibilityIan Olver, Margaret Davy, Diana Lüftner, So-Hyang Park, Merrill Egorin, Andrew Ellis, Lorraine Webster
dc.identifier.citationCancer Chemotherapy and Pharmacology, 2001; 48(2):109-114
dc.identifier.doi10.1007/s002800000263
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.orcidOlver, I. [0000-0001-5478-1576]
dc.identifier.urihttp://hdl.handle.net/2440/9343
dc.language.isoen
dc.publisherSpringer
dc.rights© Springer, Part of Springer Science+Business Media
dc.source.urihttps://doi.org/10.1007/s002800000263
dc.subjectPaclitaxel
dc.subjectAltretamine
dc.subjectOvarian cancer
dc.subjectPharmacokinetics
dc.titleA phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications